Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.

Gastroenterology - 1 Oct 2008

Grudell April B M, Sweetser Seth, Camilleri Michael, Eckert Deborah J, Vazquez-Roque Maria I, Carlson Paula J, Burton Duane D, Braddock Autumn E, Clark Matthew M, Graszer Karen M, Kalsy Sarah A, Zinsmeister Alan R

Abstract excerpt

BACKGROUND & AIMS: Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate alpha2A adrenoreceptor, 5-HT transporter, and GNbeta3 genes and weight loss with sibutramine. METHODS: We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Composition
Share to Feeding Behavior

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterotrimeric GTP-Binding Proteins

Share to Obesity

Share to Overweight

Share to Receptors, Adrenergic, alpha-2

Share to Serotonin Plasma Membrane Transport Proteins

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 18725220
DOI: 10.1053/j.gastro.2008.07.009
PMCID: PMC2629484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.PMID 18725220Read ↗

Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism.Semantic proximity Read ↗

Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.Semantic proximity Read ↗

Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.Semantic proximity Read ↗

Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.Semantic proximity Read ↗

Effect of the G-protein β3 subunit 825T allele on the change of body adiposity in obese female.Semantic proximity Read ↗

Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women.Semantic proximity Read ↗

Genotype-specific weight loss treatment advice: how close are we?Semantic proximity Read ↗

Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine.Semantic proximity Read ↗

Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects.Semantic proximity Read ↗

Pharmacogenetics of obesity drug therapy.Semantic proximity Read ↗

Serotonin Transporter Gene Polymorphisms Predict Adherence to Weight Loss Programs Independently of Obesity-Related GenesSemantic proximity Read ↗

Associations between Genotype-Diet Interactions and Weight Loss-A Systematic Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.